Alliancebernstein L.P. lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,286,994 shares of the company's stock after buying an additional 84,255 shares during the quarter. Alliancebernstein L.P. owned about 2.89% of Viridian Therapeutics worth $43,842,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. Pictet Asset Management Holding SA lifted its position in shares of Viridian Therapeutics by 21.8% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,248,721 shares of the company's stock worth $23,938,000 after buying an additional 223,384 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Viridian Therapeutics in the 4th quarter valued at $26,845,000. BIT Capital GmbH raised its position in Viridian Therapeutics by 239.8% in the 4th quarter. BIT Capital GmbH now owns 285,954 shares of the company's stock valued at $5,482,000 after purchasing an additional 201,808 shares during the last quarter. Corebridge Financial Inc. raised its position in Viridian Therapeutics by 8.6% in the 4th quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock valued at $697,000 after purchasing an additional 2,878 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Viridian Therapeutics by 4.0% in the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after purchasing an additional 174,952 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research firms recently commented on VRDN. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Royal Bank of Canada upped their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.
Check Out Our Latest Report on VRDN
Viridian Therapeutics Price Performance
Shares of NASDAQ:VRDN traded down $0.82 on Thursday, reaching $10.98. 210,967 shares of the company were exchanged, compared to its average volume of 1,185,549. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The firm has a market cap of $894.30 million, a price-to-earnings ratio of -2.56 and a beta of 0.81. The company has a 50-day moving average of $15.39 and a 200-day moving average of $19.08.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
Viridian Therapeutics Company Profile
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
